Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

How did Novo Nordisk get to the position it’s in now — with its stock halved over the past year and the company widely seen as trailing Eli Lilly in the weight loss market it once led?

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months. Lilly's experimental obesity drug shows promise in early studies - Los Angeles ...

Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, ...